NAV

4-oxo-4,5-dihydro-1,2,5-thiadiazole-3-carboxylic acid

Identification

Generic Name
4-oxo-4,5-dihydro-1,2,5-thiadiazole-3-carboxylic acid
DrugBank Accession Number
DB03162
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 146.125
Monoisotopic: 145.97861263
Chemical Formula
C3H2N2O3S
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UL-lactate dehydrogenaseNot AvailablePlasmodium falciparum (isolate CDC / Honduras)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as thiadiazoles. These are cyclic organic compounds containing a thiadiazole ring, which is a five-membered aromatic heterocycle made up of one sulfur atom and two nitrogen atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Thiadiazoles
Direct Parent
Thiadiazoles
Alternative Parents
Vinylogous amides / Heteroaromatic compounds / Lactams / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Aromatic heteromonocyclic compound / Azacycle / Carboxylic acid / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxide
show 6 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
thiadiazolecarboxylic acid (CHEBI:42691)
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
45654-48-6
InChI Key
FVZITYNLUYJDOE-UHFFFAOYSA-N
InChI
InChI=1S/C3H2N2O3S/c6-2-1(3(7)8)4-9-5-2/h(H,5,6)(H,7,8)
IUPAC Name
4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid
SMILES
OC(=O)C1=NSN=C1O

References

General References
Not Available
PubChem Compound
448652
PubChem Substance
46505443
ChemSpider
395386
BindingDB
23251
ChEMBL
CHEMBL1232973
ZINC
ZINC000006523896
PDBe Ligand
GBD
PDB Entries
1t26

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.27 mg/mLALOGPS
logP-0.26ALOGPS
logP1.34Chemaxon
logS-1.4ALOGPS
pKa (Strongest Acidic)1.32Chemaxon
pKa (Strongest Basic)-3.1Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area83.31 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity30.01 m3·mol-1Chemaxon
Polarizability11.43 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9739
Blood Brain Barrier+0.8414
Caco-2 permeable-0.6133
P-glycoprotein substrateNon-substrate0.7213
P-glycoprotein inhibitor INon-inhibitor0.971
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9514
CYP450 2C9 substrateNon-substrate0.7332
CYP450 2D6 substrateNon-substrate0.8199
CYP450 3A4 substrateNon-substrate0.7768
CYP450 1A2 substrateNon-inhibitor0.6641
CYP450 2C9 inhibitorNon-inhibitor0.8252
CYP450 2D6 inhibitorNon-inhibitor0.8925
CYP450 2C19 inhibitorNon-inhibitor0.7779
CYP450 3A4 inhibitorNon-inhibitor0.8755
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9616
Ames testNon AMES toxic0.6828
CarcinogenicityNon-carcinogens0.8885
BiodegradationNot ready biodegradable0.6446
Rat acute toxicity2.3426 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9926
hERG inhibition (predictor II)Non-inhibitor0.9559
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00fs-9500000000-32508ba81c2bcd73a717
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0900000000-aa8f46eb5a9b11fdce74
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-006x-9000000000-5393aaa759e6411aac2b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fb9-2900000000-4247547d599fe3068cf7
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-c190a1fdd88847136561
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00fs-9000000000-1bda5c45c6142a100a9a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dl-9000000000-b72073c3f8b68939d0c5
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-123.93202
predicted
DeepCCS 1.0 (2019)
[M+H]+126.05829
predicted
DeepCCS 1.0 (2019)
[M+Na]+134.47473
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. L-lactate dehydrogenase
Kind
Protein
Organism
Plasmodium falciparum (isolate CDC / Honduras)
Pharmacological action
Unknown
General Function
L-lactate dehydrogenase activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q27743
Uniprot Name
L-lactate dehydrogenase
Molecular Weight
34107.505 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52